Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India

Indian Journal of Cancer

Volumn 48, Issue 4, 2011, Pages 391-396

  Ghosh, J ^a   Gupta, S ^a   Desai, S ^a   Shet, T ^a   Radhakrishnan, S ^a   Suryavanshi, P ^a   Parmar, V ^a   Jalali, R ^a   Goyal, G ^a   Hawaldar, R ^a   Patil, A ^a   Nair, N ^a   Badwe, R A ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

HER2 targeted therapy; India; triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; NERATINIB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); ELECTRONIC MEDICAL RECORD; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HOSPITAL PHARMACY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; INDIA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; COST OF ILLNESS; ELECTRONIC HEALTH RECORDS; ESTROGENS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOHISTOCHEMISTRY; INDIA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGESTERONE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84863147713     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.92245     Document Type: Article

References (16)

1. National Cancer Registry Programme, Indian Council of Medical Research. Leading sites of cancer. In, Consolidated Report of Population Based Cancer Registries 2001-2004, Incidence and Distribution of Cancer. Bangalore: Coordinating Unit, National Cancer Registry Programme (ICMR); 2006. p. 8-30.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
3. Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462-9. (Pubitemid 28135587)
4. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48. (Pubitemid 29415219)
5. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36. (Pubitemid 46039831)
6. Shousha S, Coady AT, Stamp T, James KR, Alaghband-Zadeh J. Oestrogen receptors in mucinous carcinoma of the breast: An immunohistological study using paraffin wax sections. J Clin Pathol 1989;42:902-5. (Pubitemid 19225446)
7. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
8. Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, Basak R, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization and immunohistochemistry: Experience of a tertiary cancer referral centre in India. Indian J Med Res 2010;132:287-94.
9. SEER Cancer Statistics Review Internet. Altekruse SF, Kosary CL, Krapcho M, et al, editors. SEER Cancer Statistics Review 1975-2007. National Cancer Institute. Bethesda. based on November 2009 SEER data submission, posted to the SEER web site, 2010. Last cited on 2010 Nov 26. Availaible from: http://seer.cancer.gov/csr/1975-2007/. Last accessed on 2011 June 04.
10. Populationcommission.nic.in Internet. India: National Commission on Population, Government of India; c2000 Last updated on 2003 Sep 11; cited on 2010 Nov 26. Availaible from: http://populationcommission.nic.in/facts1.htm. Last accessed on 2011 June 04.
11. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value and mammographic screening. J Clin Pathol 2000;53:688-96.
12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. (Pubitemid 47219710)
13. Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 2011;12:625-9.
14. Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G. ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Can 2010;47:8-15.
15. Indiabudget.nic.in Internet. India: Economic Survey, Ministry of Finance, Government of India; c2009-10 Last updated on 2011 June 13; Last cited on 2011 Jan 25. Availaible from: http://indiabudget.nic.in/survey.asp. Last accessed on 2011 June 04.
16. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A model-based analysis of the HERA and FinHer trial. Ann Oncol 2007;18:1493-9. (Pubitemid 47365481)